Abstract
Left ventricular (LV) diastolic dysfunction is an important contributor to many different cardiovascular diseases. LV diastolic dysfunction can manifest itself as slow LV relaxation, slow LV filling or high diastolic LV stiffness. Diastolic abnormalities have been described in the senescent heart, in heart failure with preserved ejection fraction (HFPEF), in diabetic cardiomyopathy, in aortic valve stenosis (AVS), in hypertrophic cardiomyopathy (HCM), as well as in Fabry disease (FD), however, exact cellular and molecular alterations behind the diastolic deterioration in these diseases are not yet completely characterized. Several studies thoroughly investigated altered cardiomyocyte function, changes of contractile myofilaments, extracellular collagen deposition and advanced glycation end products (AGEs) cross-linking in the background of diastolic dysfunction. These clinical and experimental data suggest that underlying mechanisms of LV diastolic dysfunction are divergent in different cardiac pathologies, therefore the present review aims to summarize mechanisms at the cellular level of diastolic abnormalities in various cardiovascular diseases.
Keywords: Cardiomyocytes, contractile dysfunction, diabetes mellitus, diastole, fibrosis, human heart
Current Pharmaceutical Biotechnology
Title:Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Volume: 13 Issue: 13
Author(s): Daniel Czuriga, Walter J. Paulus, Istvan Czuriga, Istvan Edes, Zoltan Papp and Attila Borbely
Affiliation:
Keywords: Cardiomyocytes, contractile dysfunction, diabetes mellitus, diastole, fibrosis, human heart
Abstract: Left ventricular (LV) diastolic dysfunction is an important contributor to many different cardiovascular diseases. LV diastolic dysfunction can manifest itself as slow LV relaxation, slow LV filling or high diastolic LV stiffness. Diastolic abnormalities have been described in the senescent heart, in heart failure with preserved ejection fraction (HFPEF), in diabetic cardiomyopathy, in aortic valve stenosis (AVS), in hypertrophic cardiomyopathy (HCM), as well as in Fabry disease (FD), however, exact cellular and molecular alterations behind the diastolic deterioration in these diseases are not yet completely characterized. Several studies thoroughly investigated altered cardiomyocyte function, changes of contractile myofilaments, extracellular collagen deposition and advanced glycation end products (AGEs) cross-linking in the background of diastolic dysfunction. These clinical and experimental data suggest that underlying mechanisms of LV diastolic dysfunction are divergent in different cardiac pathologies, therefore the present review aims to summarize mechanisms at the cellular level of diastolic abnormalities in various cardiovascular diseases.
Export Options
About this article
Cite this article as:
Czuriga Daniel, J. Paulus Walter, Czuriga Istvan, Edes Istvan, Papp Zoltan and Borbely Attila, Cellular Mechanisms for Diastolic Dysfunction in the Human Heart, Current Pharmaceutical Biotechnology 2012; 13 (13) . https://dx.doi.org/10.2174/1389201011208062532
DOI https://dx.doi.org/10.2174/1389201011208062532 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2
Current Pharmacogenomics Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Modulation of the Rho/ROCK Pathway in Heart and Lung after Thorax Irradiation Reveals Targets to Improve Normal Tissue Toxicity
Current Drug Targets Cord Blood as Diagnostic Window for Preeclampsia
Recent Patents on Biomarkers A Survey on Left Ventricle Segmentation Techniques in Cardiac Short Axis MRI
Current Medical Imaging Heme Oxygenase-1/CO as Protective Mediators in Cigarette Smoke- Induced Lung Cell Injury and Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Biotechnology Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Pharmacological Targeting in Inherited Arrhythmia Syndromes
Current Medicinal Chemistry Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine A Review of Patents on Implantable Heart-Compression/Assist Devices and Systems
Recent Patents on Biomedical Engineering (Discontinued) Dimerization and Ion Binding Properties of S100P Protein
Protein & Peptide Letters Autoantibodies for Cardiac Channels and Sudden Cardiac Death and its Relationship to Autoimmune Disorders
Current Cardiology Reviews microRNAs in Cardiovascular Disease: Small Molecules but Big Roles
Current Topics in Medicinal Chemistry Antioxidant Therapy Against Trypanosome Infections: A Review Update
Current Topics in Medicinal Chemistry Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets Cardiac Regeneration: Stem Cells and Beyond
Current Medicinal Chemistry